Exploring the human plasma proteome for humoral mediators of remote ischemic preconditioning - A word of caution

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Helgeland, Erik ^a   Breivik, Lars Ertesvag ^a   Vaudel, Marc ^a   Svendsen, Øyvind Sverre ^b   Garberg, Hilde ^a   Nordrehaug, Jan Erik ^a   Berven, Frode Steingrimsen ^a   Jonassen, Anne Kristine ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; COMPLEMENT COMPONENT C2; CYSTEINE RICH SECRETORY PROTEIN 3; FIBRONECTIN; HAPTOGLOBIN; HUMORAL ANTIBODY; KALLISTATIN; LACTOYLGLUTATHIONE LYASE; PLASMA PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; ARTIFACT; BIOINFORMATICS; CLINICAL DATA REPOSITORY; CONTROLLED STUDY; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; ISCHEMIC PRECONDITIONING; MALE; MEDIATOR RELEASE; NORMAL HUMAN; PLASMA; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FOLDING; PROTEOMICS; QUANTITATIVE STUDY; REMOTE ISCHEMIC PRECONDITIONING; METABOLISM; PROCEDURES; PROTEIN DATABASE;

DATABASES, PROTEIN; HUMANS; ISCHEMIC PRECONDITIONING; PROTEOME; PROTEOMICS;

EID: 84908042368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109279     Document Type: Article

References (77)

1. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, et al. (2010) Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375: 727-734.
2. Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, et al. (2006) Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 47: 2277-2282.
3. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, et al. (2007) Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 370: 575-579.
4. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, et al. (2010) Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 105: 657-664.
5. Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, et al. (2009) Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. Heart 95: 1567-1571.
6. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, et al. (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382: 597-604.
7. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, et al. (2012) STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res 110: 111-115.
8. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD (1996) Myocardial protection by brief ischemia in noncardiac tissue. Circulation 94: 2193-2200.
9. McClanahan TB, Nao BS, Wolke LJ, Martin BJ, T E., Mertz aKPG (1993) Brief renal occlusion and reperfusion induces myocardial infarct size in rabbits. FASEB J 7.
10. Weinbrenner C, Nelles M, Herzog N, Sarvary L, Strasser RH (2002) Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway.Cardiovasc Res 55: 590-601.
11. Breivik L, Helgeland E, Aarnes EK, Mrdalj J, Jonassen AK (2010) Remote postconditioning by humoral factors in effluent from ischemic preconditioned rat hearts is mediated via PI3K/Akt-dependent cell-survival signaling at reperfusion. Basic Res Cardiol 106: 135-145.
12. Dickson EW, Lorbar M, Porcaro WA, Fenton RA, Reinhardt CP, et al. (1999) Rabbit heart can be "preconditioned" via transfer of coronary effluent. Am J Physiol 277: H2451-2457.
13. Serejo FC, Rodrigues LF, Jr., da Silva Tavares KC, de Carvalho AC, Nascimento JH (2007) Cardioprotective properties of humoral factors released from rat hearts subject to ischemic preconditioning. J Cardiovasc Pharmacol 49: 214-220.
14. Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, et al. (2001) Naloxone blocks transferred preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 33: 1751-1756.
15. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, et al. (2009) Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 117: 191-200.
16. Lim SY, Yellon DM, Hausenloy DJ (2010) The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol 105: 651-655.
17. Hepponstall M, Ignjatovic V, Binos S, Monagle P, Jones B, et al. (2012) Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans. PLoS One 7: e48284.
18. Pang T, Zhao Y, Zhang NR, Jin SQ, Pan SQ (2013) Transient limb ischemia alters serum protein expression in healthy volunteers: complement C3 and vitronectin may be involved in organ protection induced by remote ischemic preconditioning. Oxid Med Cell Longev 2013: 859056.
19. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, et al. (2013) Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning. PLoS One 8: e77211.
20. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, et al. (2014) Modifications in rat plasma proteome after remote ischemic preconditioning (RIPC) stimulus: identification by a SELDI-TOF-MS approach. PLoS One 9: e85669.
21. Davidson SM, Selvaraj P, He D, Boi-Doku C, Yellon RL, et al. (2013) Remote ischaemic preconditioning involves signalling through the SDF-1alpha/CXCR4 signalling axis. Basic Res Cardiol 108: 377.
22. Przyklenk K (2013) 'Going out on a limb': SDF-1alpha/CXCR4 signaling as a mechanism of remote ischemic preconditioning? Basic Res Cardiol 108: 382.
23. Gosho M, Nagashima K, Sato Y (2012) Study designs and statistical analyses for biomarker research. Sensors (Basel) 12: 8966-8986.
24. Aebersold R, Burlingame AL, Bradshaw RA (2013) Western blots versus selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics 12: 2381-2382.
25. Kinsinger CR, Apffel J, Baker M, Bian X, Borchers CH, et al. (2012) Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles). J Proteome Res 11: 1412-1419.
26. Martens L, Nesvizhskii AI, Hermjakob H, Adamski M, Omenn GS, et al. (2005) Do we want our data raw? Including binary mass spectrometry data in public proteomics data repositories. Proteomics 5: 3501-3505.
27. Vizcaino JA, Deutsch EW, Wang R, Csordas A, Reisinger F, et al. (2014) ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotech 32: 223-226.
28. Barsnes H, Martens L (2013) Crowdsourcing in proteomics: public resources lead to better experiments. Amino Acids 44: 1129-1137.
29. Phillips HL, Williamson JC, van Elburg KA, Snijders AP, Wright PC, et al. (2010) Shotgun proteome analysis utilising mixed mode (reversed phase-anion exchange chromatography) in conjunction with reversed phase liquid chromatography mass spectrometry analysis. Proteomics 10: 2950-2960.
30. Kessner D, Chambers M, Burke R, Agus D, Mallick P (2008) ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 24: 2534-2536.
31. Geer LY, Markey SP, Kowalak JA, Wagner L, Xu M, et al. (2004) Open mass spectrometry search algorithm. J Proteome Res 3: 958-964.
32. Craig R, Beavis RC (2004) TANDEM: matching proteins with tandem mass spectra. Bioinformatics 20: 1466-1467.
33. Vaudel M, Barsnes H, Berven FS, Sickmann A, Martens L (2011) SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. Proteomics 11: 996-999.
34. Elias JE, Gygi SP (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4: 207-214.
35. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 32: D115-119.
36. Barsnes H, Vaudel M, Colaert N, Helsens K, Sickmann A, et al. (2011) compomics-utilities: an open-source Java library for computational proteomics. BMC Bioinformatics 12: 70.
37. Vizcaino JA, Cote RG, Csordas A, Dianes JA, Fabregat A, et al. (2013) The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res 41: D1063-1069.
38. Martens L, Hermjakob H, Jones P, Adamski M, Taylor C, et al. (2005) PRIDE: the proteomics identifications database. Proteomics 5: 3537-3545.
39. Vaudel M, Sickmann A, Martens L (2010) Peptide and protein quantification: a map of the minefield. Proteomics 10: 650-670.
40. Vaudel M, Sickmann A, Martens L (2013) Introduction to opportunities and pitfalls in functional mass spectrometry based proteomics. Biochim Biophys Acta.
41. Burkhart JM, Vaudel M, Zahedi RP, Martens L, Sickmann A (2011) iTRAQ protein quantification: a quality-controlled workflow. Proteomics 11: 1125-1134.
42. Powell DW, Weaver CM, Jennings JL, McAfee KJ, He Y, et al. (2004) Cluster analysis of mass spectrometry data reveals a novel component of SAGA. Mol Cell Biol 24: 7249-7259.
43. Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, et al. (2012) The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 120: e73-82.
44. Yadav AK, Bhardwaj G, Basak T, Kumar D, Ahmad S, et al. (2011) A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLoS One 6: e24442.
45. Hausenloy DJ (2013) Cardioprotection techniques: preconditioning, postconditioning and remote con-ditioning (basic science). Curr Pharm Des 19: 4544-4563.
46. Heusch G (2013) Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381: 166-175.
47. Przyklenk K (2013) Reduction of Myocardial Infarct Size with Ischemic "Conditioning": Physiologic and Technical Considerations. Anesth Analg.
48. Cote RG, Jones P, Martens L, Kerrien S, Reisinger F, et al. (2007) The Protein Identifier Cross-Referencing (PICR) service: reconciling protein identifiers across multiple source databases. BMC Bioinformatics 8: 401.
49. Zhou GX, Chao L, Chao J (1992) Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267: 25873-25880.
50. Chao J, Stallone JN, Liang YM, Chen LM, Wang DZ, et al. (1997) Kallistatin is a potent new vasodilator. J Clin Invest 100: 11-17.
51. Gao L, Yin H, S. Smith R J, Chao L, Chao J (2008) Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 88: 1157-1166.
52. Chao J, Yin H, Yao YY, Shen B, Smith RS, Jr., et al. (2006) Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 17: 1201-1213.
53. Shen B, Gao L, Hsu YT, Bledsoe G, Hagiwara M, et al. (2010) Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol 299: H1419-1427.
54. Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, et al. (2012) Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 303: F1230-1238.
55. Renaux JL, Thomas M, Crost T, Loughraieb N, Vantard G (1999) Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Kidney Int 55: 1097-1103.
56. Dray A, Perkins M (1993) Bradykinin and inflammatory pain. Trends Neurosci 16: 99-104.
57. Dietze GJ, Wicklmayr M, Rett K, Jacob S, Henriksen EJ (1996) Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 45 Suppl 1: S110-114.
58. Boix F, Rosenborg L, Hilgenfeldt U, Knardahl S (2002) Contraction-related factors affect the concentration of a kallidin-like peptide in rat muscle tissue. J Physiol 544: 127-136.
59. Edery H, Lewis GP (1962) Inhibition of plasma kininase activity at slightly acid ph. Br J Pharmacol Chemother 19: 299-305.
60. Saxena P, Shaw OM, Misso NL, Naran A, Shehatha J, et al. (2011) Remote ischemic preconditioning stimulus decreases the expression of kinin receptors in human neutrophils. J Surg Res 171: 311-316.
61. Weisman HF, Bartow T, Leppo MK, Marsh HC, Jr., Carson GR, et al. (1990) Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146-151.
62. Diepenhorst GM, van Gulik TM, Hack CE (2009) Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg 249: 889-899.
63. Pemberton M, Anderson G, Vetvicka V, Justus DE, Ross GD (1993) Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol 150: 5104-5113.
64. Wada K, Montalto MC, Stahl GL (2001) Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 120: 126-133.
65. Zhao H, Montalto MC, Pfeiffer KJ, Hao L, Stahl GL (2002) Murine model of gastrointestinal ischemia associated with complement-dependent injury. J Appl Physiol (1985) 93: 338-345.
66. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, et al. (2003) Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162: 449-455.
67. Karpel-Massler G, Fleming SD, Kirschfink M, Tsokos GC (2003) Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 115: 247-256.
68. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, et al. (2011) Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 108: 7523-7528.
69. Bossi F, Peerschke EI, Ghebrehiwet B, Tedesco F (2011) Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett 140: 7-13.
70. Engelbrecht B, Stratmann B, Hess C, Tschoepe D, Gawlowski T (2013) Impact of GLO1 knock down on GLUT4 trafficking and glucose uptake in L6 myoblasts. PLoS One 8: e65195.
71. Inagi R, Kumagai T, Fujita T, Nangaku M (2010) The role of glyoxalase system in renal hypoxia. Adv Exp Med Biol 662: 49-55.
72. Ahmed U, Dobler D, Larkin SJ, Rabbani N, Thornalley PJ (2008) Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro. Ann N Y Acad Sci 1126: 262-264.
73. Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95: 233-238.
74. Udby L, Sorensen OE, Pass J, Johnsen AH, Behrendt N, et al. (2004) Cysteinerich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma. Biochemistry 43: 12877-12886.
75. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, et al. (2007) Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation 116: 1386-1395.
76. Hong DM, Jeon Y, Lee CS, Kim HJ, Lee JM, et al. (2012) Effects of remote ischemic preconditioning with postconditioning in patients undergoing off-pump coronary artery bypass surgery-randomized controlled trial. Circ J 76: 884-890.
77. The Remote Preconditioning Trialists G, Healy DA, Khan WA, Wong CS, Moloney MC, et al. (2014) Remote preconditioning and major clinical complications following adult cardiovascular surgery: Systematic review and meta-analysis. Int J Cardiol.